Table 1. Range of expected therapeutic warfarin doses based on CYP2C9 and VKORC1 genotypes as described in a US FDA drug label.
| Genotype |
CYP2C9
|
||||||
|---|---|---|---|---|---|---|---|
|
*1/*1
(mg/day) |
*1/*2
(mg/day) |
*1/*3
(mg/day) |
*2/*2
(mg/day) |
*2/*3
(mg/day) |
*3/*3
(mg/day) |
||
| VKORC1 | GG | 5–7† | 5–7† | 3–4 | 3–4 | 3–4 | 0.5–2† |
| AG | 5–7† | 3–4 | 3–4 | 3–4 | 0.5–2† | 0.5–2† | |
| AA | 3–4 | 3–4 | 0.5–2† | 0.5–2† | 0.5–2† | 0.5–2† | |
†
Dosage recommendations deviate from standard dosage recommendations because of pharmacogenetic findings.
Reproduced from the updated warfarin (Coumadin, Bristol–Myers Squibb, Princeton, NJ, USA) product label.